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Abstract 
 
Aims: To explore whether long-term intervention with dietary nitrate ((NO3
-
), a potential 
tolerance-free source of beneficial vasoactive nitric oxide) and spironolactone (to oppose 
aldosterone’s potential deleterious cardiovascular effects) improve cardiac structure/function, 
independent of blood pressure (BP), in patients with/at risk of type 2 diabetes (a population at 
risk of heart failure).  
Methods: A sub-sample of participants in our double-blind, randomised, factorial-design 
intervention (VaSera) trial of active beetroot juice as a nitrate source (≤11.2 mmol) or 
placebo (nitrate-depleted) beetroot juice, and either ≤50 mg spironolactone or ≤16 mg 
doxazosin (control), had trans-thoracic cardiac ultrasounds at baseline (n=105), 3 and 6 
months (n=87) of intervention. Analysis was by modified intention-to-treat.  
Results: Nitrate-containing juice (n=40) decreased left ventricular (LV) end diastolic volume: 
-6.3 mL (95% confidence intervals (CI) -11.1,-1.6), and end systolic volume: -3.2 mL (-5.9,-
0.5), and increased end diastolic mass/volume ratio: +0.04 (0.00,0.07), relative to placebo 
juice (n=47). Spironolactone (n=44) reduced relative wall thickness compared to doxazosin 
(n=43): -0.01 (-0.02,-0.00). Whilst spironolactone reduced LV mass index relative to 
baseline: -1.48 g/m
2.7 
(-2.08,-0.88), there was no difference versus doxazosin: -0.85 g/m
2.7
 (-
1.76,0.05). Spironolactone also decreased the E/A ratio: -0.12 (-0.19,-0.04) and increased S’ 
(a tissue-Doppler systolic function index) by 0.52 (0.05,1.0 cm/s). BP did not differ between 
the juices, or between the drugs. 
Conclusions: 6 months' dietary nitrate decreased LV volumes ~5%, representing new, 
sustained, BP-independent benefits on cardiac structure, extending mechanisms characterised 
in pre-clinical models of heart failure. Spironolactone’s effects on cardiac remodeling and 
systo-diastolic function whilst confirmatory, were independent of BP. 
 
  
This article is protected by copyright. All rights reserved. 
Key words: dietary nitrate, beetroot juice, echocardiography, cardiac remodelling, nitrate-
nitrite-NO pathway, type 2 diabetes,  
 
What is already known about this subject: 
 Type 2 Diabetes (T2DM) is a major risk factor for heart failure (HF), especially with 
preserved ejection fraction (HFpEF), for which there are no established cures 
 Acutely, inorganic nitrite improves central haemodynamics and left heart filling 
pressures in patients with HFpEF 
 Chronic administration of nitrite (4 and 9 weeks’) in murine models of heart failure 
reduces left ventricular (LV) volumes 
What this study adds: 
 In the longest study yet completed with dietary nitrate, 6 months’ beetroot juice 
decreased LV volumes ~5% 
 This was independent of blood pressure and represents a sustained beneficial effect on 
cardiac structure 
 Dietary nitrate has potential to prevent diabetic cardiomyopathy/heart failure 
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Introduction 
 
Type 2 Diabetes (T2DM) is a major risk factor for heart failure (HF) [1], with either reduced 
(HFrEF) or preserved ejection fraction (HFpEF) [2].  Patients with T2DM are particularly 
susceptible to increased LV volumes with drugs which cause fluid retention/increase pre-
load, such as pioglitazone [3]. Conversely, simply lowering BP with losartan or atenolol in 
the LIFE study did not alter LV volumes in patients with diabetes [4].  
 
Decreased production of nitric oxide (NO) [5, 6], a key regulator of vascular homeostasis, by 
NO synthases and/or decreased bioavailability of NO, (eg: due to excess reactive oxygen 
species, ROS), is implicated in vascular dysfunction in cardiovascular disease and T2DM [7], 
LV diastolic dysfunction [8], HF [9], and HFpEF [10]. However, standard approaches to 
supplement NO using organic nitrates, such as isosorbide mononitrate, lack benefit [11]. This 
loss of effect with chronic ingestion may be due to nitrate tolerance via decreased 
bioactivation, increased ROS production and endothelial dysfunction [12]. An alternative 
therapeutic approach may be via dietary inorganic nitrate (NO3
-
), as found in green leafy 
vegetables and beetroot [13]. Nitrate is reduced to nitrite (NO2
-
) via the entero-salivary 
circulation, and further reduced to NO in a hypoxia-dependent process. This “nitrate-nitrite-
NO pathway” appears to lack these tolerance issues [14], suppress ROS [15] and reverse 
endothelial dysfunction [16], and has been extensively investigated clinically in studies up to 
4-6 weeks, particularly for blood pressure (BP)-lowering [14, 16-19]. By contrast, patients 
with T2DM appear to lack any effect of dietary nitrate on BP [19-21].   
 
However, we recently reported that dietary nitrate lowered central aortic systolic BP (–2.6 
mm Hg [–4.5 to –0.75 mm Hg], (mean [95% CIs]) p=0.007), despite no effect on brachial 
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BP, with the main haemodynamic findings of the current study [22]. This is consistent with 
our findings whereby inorganic nitrite acutely and selectively lowers central aortic pressure 
through a normoxia-dependent dilatory effect on conduit arteries (radial) in healthy 
volunteers [23, 24], and selectively dilates epicardial coronary arteries in patients undergoing 
coronary angiography [25].  
 
Another important cause of heart failure in patients with T2DM is myocardial infarction due 
to coronary artery disease, with nitrite displaying a potential role  in coronary ischaemia-
reperfusion injury (IRI) [26], acute ST-elevation myocardial infarction (STEMI) [27, 28], and 
remote ischaemic preconditioning (RIPC) [29, 30]. Moreover, Lefer and colleagues showed 
that chronic, 4-9 weeks’ oral sodium nitrite supplementation prevented the increases in end-
diastolic volume (EDV) and end-systolic volume (ESV)) in murine models of IRI following 
left coronary artery occlusion  [31], and pressure-overload induced LVH with trans-aortic 
constriction  [9].  
 
In contrast to NO-supplementation, mineralocorticoid antagonists are established treatments 
in HF and hypertension, combatting aldosterone-mediated deleterious cardiovascular effects 
[32], with 40 weeks’ spironolactone [5, 33] improving LV mass, arterial stiffness measured 
as pulse wave velocity (PWV), augmentation index, and aortic distensibility, in parallel with 
the reduction in BP, over in patients with stage 2-3 chronic kidney disease [34].  
 
Given the potential for long-term dietary nitrate, and spironolactone, to improve cardiac 
structure or function, alongside, or independently of, any changes in arterial haemodynamics, 
we prospectively performed echocardiograms in a sub-sample of patients participating in our 
VaSera factorial RCT [22, 35], with the a priori intention of exploring these specific 
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mechanisms independently of BP, following a chronic, 6 months’ treatment  with dietary 
nitrate (‘Beet-it®’ or ‘Beet-it Sport®’ beetroot juice), and/or spironolactone.  
 
The primary hypothesis for the main study was that spironolactone, dietary nitrate, or both 
could reduce arterial stiffness, measured by PWV, as a treatment target formally independent 
of BP. We have recently reported that the primary outcome, change in arterial stiffness as 
cardio-ankle vascular index (CAVI), a nominally BP-independent measure, was not different 
between spironolactone and doxazosin [5, 36], P=0.08 [22]. Also, and against the hypothesis, 
the secondary outcome, aortic PWV by arteriography adjusted for peripheral BP differences 
at baseline and BP change between trial arms from the trial’s start to end, was lower with 
doxazosin than spironolactone (P=0.045). Dietary nitrate had no effect on PWV.  
 
Methods 
 
Study Population 
A sub-sample of patients (with, or at risk of, T2DM) who were consented and randomised in 
our VaSera factorial RCT had serial trans thoracic cardiac ultrasound performed during the 
course of the study. The study design and methods have previously been described in detail 
[35]. Briefly, participants with or at risk of T2DM were recruited from Guy’s and St Thomas’ 
Hospitals, London, UK and surrounding areas between 2013-2015. Inclusion criteria were 
age 18-80 years, clinically diagnosed T2DM or at risk of T2DM (as body mass index (BMI) 
≥27 kg/m2, positive family history or glucose intolerance after 75g challenge), ability to 
understand and comply with the protocol. Exclusion criteria: interfering chronic illness, 
adverse reaction to either drug, known allergy to beetroot, eGFR <45 mL min-1, HbA1c 
>11% (97mM/M), pregnant, breast feeding or atrial fibrillation.  
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The results for the primary outcome – (arterial stiffness) are described above and have  been 
published separately [22].  The study was reviewed and approved by Central London 
National Research Ethics Service (NRES) and took place in the Clinical Research Facility 
(CRF) of St Thomas’s Hospital. (Clinical trial registration: ISRCTN25003627/ DOI 
10.1186/ISRCTN25003627). After initial consent and screening/familiarisation, visit 1 (V1), 
and having met inclusion criteria, patients were invited to return for double randomisation (in 
blocks of 6) at visit 2 (V2), with simultaneous allocation to both types of intervention for 
each patient, therefore into 1 of 4 groups [35]; see Figure 1 for Study Flow Diagram. After 
cardiac and vascular measurements, treatments were: either spironolactone 12.5mg once daily 
for one week titrated to twice daily, OR doxazosin 2mg once daily for one week titrated to 
twice daily, AND either nitrate -containing beetroot juice (BEET-IT®, nitrate 4.5mmol/day) 
or placebo beetroot juice. The juices were identical in appearance, smell and taste, with the 
nitrate having been removed from placebo juice by ion exchange (nitrate ~0mmol/day). 
Following two check-up visits (V3 and V4; 2 and 8 weeks, respectively), cardiac and 
vascular measures were repeated at 3 months (V5). Then, provided there were no 
contraindications, medication doses were increased (to spironolactone 25mg twice daily or 
doxazosin 8mg twice daily) and to more concentrated nitrate -containing beetroot juice 
(BEET-IT® Elite Sports Shot, ~11.2mmol nitrate/day, or matching placebo juice, ~0 mmol 
nitrate/day). The final visit (V6) was at 6 months’ post-randomisation, when V2 and V5 
cardiovascular assessments were repeated.  
Thus, in this factorial design, approximately half the patients were randomised to active, 
nitrate-containing beetroot juice, and the other half to the placebo nitrate-depleted juice (with 
no difference in BP expected, based on other studies of dietary nitrate in patients with T2DM 
described above). Also, half the patients were randomised to spironolactone, and the other 
half to doxazosin as control (expected to produce similar changes in BP from baseline, but no 
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difference between the treatments). The factorial design is intended to permit determination 
of the independent effects of nitrate v placebo, and spironolactone v doxazosin, following 
testing for drug-dietary nitrate interactions for BP and for echocardiographic parameters.  
 
Echocardiography: Echocardiography was added to the protocol and offered to as many of 
the patients as possible, to explore mechanisms related to standard cardiac structure and 
function assessments, in parallel with the key haemodynamic outcome measures of the main 
study.  
 
Trans-thoracic cardiac ultrasound was performed using a GE Vivid 7 Ultrasound system. All 
measurements were performed by two expert operators and all images analysed by a single 
operator blinded to the intervention. Acquisitions were individually optimized for depth, gain, 
and frame rate to maximize image quality and minimize inconsistency in acoustic windows 
prior to analysis. Standard M-mode and 2D imaging was undertaken at rest. Images were 
saved in raw data format for offline analysis. Left atrial volume (LAV) was calculated by the 
ellipsoid method and subsequently normalized to body surface area to obtain left atrium 
volume index (LAVI). Recommendations of the American Society of Echocardiography and 
the European Association of Cardiovascular Imaging [37] were used to estimate left 
ventricular mass (LVM) which was indexed to height
2.7
, for LVM index (LVMI) to avoid 
systematic misclassification of cardiovascular risk in overweight and obesity - likely in these 
patients. Left ventricular ESV and EDV were measured using Simpson’s method and to 
estimate ejection fraction (EF). The ratio between LVM and EDV (mass/volume, M/V ratio) 
was calculated. Left ventricular (LV) systolic function was evaluated by peak systolic tissue 
Doppler imaging (TDI) of S’ wave (averaged between septal and later mitral annulus) and 
global longitudinal strain (GLS) assessed by 2-dimensional speckle tracking 
  
This article is protected by copyright. All rights reserved. 
echocardiography. Diastolic function of the left ventricle was estimated by conventional 
Doppler mitral inflow (ratio of transmitral Doppler early (E) to late (A) filling velocity (E/A)) 
and tissue Doppler imaging (TDI) of mitral annulus (ratio of transmitral Doppler early filling 
velocity (E) to tissue Doppler early diastolic mitral annular velocity (E′) – (E/E’)), as per 
recommendations [38] as was the ratio E/E’ for evaluating LV filling pressure.  
 
Statistical considerations  
Analyses were conducted by our independent biostatistician (SM) modified intent-to-treat, 
consisting of all randomised patients except those with no outcome data at any follow up 
visit. Patients with missing data at some visits were included, and we assumed that data were 
missing at random (i.e. unrelated to the unobserved value). We used mixed effect models to 
estimate the effect of the interventions, and included gender, age, ethnicity (European, 
African-Caribbean, West African and other), a diagnosis of diabetes and the baseline value of 
the outcome as covariates. This was a pre-specified/prospectively-conducted, hypothesis-
generating, exploratory mechanistic part of the main study.  Thus, we present least squares 
mean changes from baseline and differences between drugs and between juices averaged over 
both follow-up visits for each outcome, with 95% confidence intervals (95% CI), rather than 
as hypothesis-testing P-values, in accordance with the recent editorial, “Statistical reporting 
of clinical pharmacology research” [39].   
 
Nomenclature of Targets and Ligands  
Key protein targets and ligands in this article are hyperlinked to corresponding entries in 
http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS 
Guide to PHARMACOLOGY [5], and are permanently archived in the Concise Guide to 
PHARMACOLOGY 2017/18 [6]. 
  
This article is protected by copyright. All rights reserved. 
Results  
One hundred and five participants had echocardiograms at baseline (V2), of whom 87 (83%) 
also had follow-up data at V5 (3 months) and V6 (6 months); see Figure 2, CONSORT 
diagram. Participant details and baseline echo parameters in each treatment arm are shown in 
Table 1. Baseline LVMI (mean±SD) was 53±13.5g/m
2.7
; 52% met criteria for LV 
hypertrophy (LVH) [37], whilst 95% had normal LV filling pressure (average E/A 1±0.4, 
E/E’ 7.8±2.2).  
Haemodynamic Parameters  
Spironolactone and doxazosin both reduced systolic BP (SBP) by about 6 mmHg compared 
to baseline by with no difference between treatments (Table 2, Figure 3 (A-B)). Changes in 
diastolic BP (DBP) were also similar on each drug (~5 mmHg); see Figure 3 (C-D) with no 
change in heart rate (HR). There were no differences in brachial SBP, DBP or HR between 
nitrate-containing versus nitrate-depleted juice (Figure 4). No drug-dietary nitrate 
interactions were detected for BP or for echocardiographic parameters; therefore, the effects 
of the drugs and dietary nitrate were estimated from models with no interaction term. 
Echocardiographic Morphological Parameters 
Compared to placebo juice (n=47), nitrate-containing beetroot juice (n=40) decreased EDV: -
6.33 mL (-11.1,-1.57) and ESV: -3.2 mL (-5.9,-0.5); see Table 2 and Figure 5. Also, EDV 
and ESV decreased relative to baseline on nitrate-containing beetroot juice: -4.77 mL (-8.10,-
1.44) and -2.77 mL (-4.66,-0.89), respectively, but not on placebo juice (n=47): -1.56 mL (-
1.67,4.80) and -0.40 mL (-1.43,2.22). The reduction in LVMI from baseline was similar 
between nitrate-containing and placebo juices, with no difference between interventions.  
Therefore, the ratio between LV mass and volume – the M/V ratio, increased by 0.04 
(0.00,0.07) between active and nitrate-containing beetroot juices. Relative to baseline, LAVI 
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fell on active juice: -1.59 ml/m
2
 (-2.64,-0.54), but not placebo juice: -0.26 ml/m
2
 (-1.29,0.78); 
however, there was no difference between the interventions: -1.33(-2.83,0.17).  
 
In contrast to nitrate, the only between-group difference in morphological parameters with 
spironolactone (n=44) was a marginal reduction in relative wall thickness (RWT): -0.01(-
0.02,0.00) vs doxazosin (n=43); see Table 2. Whilst spironolactone reduced LVMI relative to 
baseline: -1.48 g/m
2.7 
(-2.08, -0.88), there was no difference versus doxazosin: -0.85 g/m
2.7
 (-
1.76,0.05). Similarly, LAVI appeared to be reduced by doxazosin relative to baseline: -1.16 
ml/m
2
 (-2.24,-0.07), but not versus spironolactone. 
 
Echocardiographic Systo-Diastolic Function 
Among parameters of systo-diastolic function, the E/A ratio fell on spironolactone from 
baseline: -0.07 (-0.12,-0.02), and versus doxazosin: -0.12 (-0.19,-0.04)); see Figure 6 (A-B).  
The tissue Doppler systolic function index, S’, increased on spironolactone versus doxazosin, 
by 0.52 cm/s (0.05, 1.00); see Figure 6 (C-D).  
The only change in systo-diastolic function parameters observed with nitrate-containing 
beetroot juice was a prolongation of the deceleration time (DT) by 19.50 ms (8.40, 30.60) and 
19.74 ms (4.47,36.01) relative to baseline and nitrate-depleted juice, respectively. 
 
Discussion  
We found that 6 months’ intervention with dietary nitrate as beetroot juice may reduce LV 
volumes (EDV and ESV) compared to placebo nitrate-depleted juice. The lack of any change 
in LV mass by active juice suggests a favourable effect of nitrate on LV structure and 
possibly myocardial wall stress (since LV volumes were reduced, whilst BP was unaffected). 
In addition, spironolactone decreased RWT, suggesting a beneficial effect on myocardial 
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remodelling, and improved parameters of systo-diastolic function (S’, E/A) compared to 
doxazosin. These effects were also independent of BP (which was not different between 
spironolactone and doxazosin).  
 Nitrate’s chronic effect on reducing LV volumes have important implications for HFpEF, 
and builds on the beneficial acute actions of nitrate/nitrite recently demonstrated on exercise 
performance and left heart filling pressures (PCWP), in patients with HFpEF [40-43]. Indeed, 
across two randomised double-blind placebo-controlled studies by Borlaug and colleagues, 
one in 28 patients [41], the other in a subset of 52 of 98 patients with HFpEF [43], who were 
undergoing invasive haemodynamic exercise testing, sodium nitrite (either intravenous or 
nebulised-inhaled) acutely decreased aortic wave reflections (at rest), improved arterial 
compliance, elastance and central hemodynamics (during exercise), and left heart filling 
pressures (pulmonary capillary wedge pressure [PCWP]), compared to placebo [41]. 
However, no clinical data are available on the long-term effects of dietary nitrate on cardiac 
structure and function. This is a key question, given the problems of tolerance associated with 
organic nitrates. Therefore, the current study provides the most extensive evidence to date of 
long-term cardiac effects of dietary nitrate and has biological plausibility, building on the 
translational study of 9 weeks’ supplementation with oral nitrite showing decreased EDV and 
ESV versus placebo in the mouse model of pressure-overload induced LVH with trans-aortic 
constriction [9]. Regarding the specific changes in ventricular volumes in our study, it can be 
speculated that dietary nitrate-derived nitrite likely acts on ventricular pre-load by influencing 
venous dilatation [24, 44], and pressure; though since nitrate salts are also known to have 
diuretic activity, this could play a role. No direct measures of pre-load were collected here; 
however, changes in indirect parameters, such as ventricular volumes, as demonstrated with 
intravenous organic nitrate therapy [45]) support this. Indeed, previous invasive studies have 
used EDV to define LV pre-load [46, 47]. Moreover, the reduction in LV volumes, but not 
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LVMI, resulted in an increased M/V ratio. This suggests a positive action on cardiac 
remodelling [48] and myocardial wall stress [49], with potential favourable prognostic 
implications [50]. 
In contrast to nitrate, ventricular volumes were not altered by spironolactone, which instead 
improved other structural and functional cardiac parameters. Spironolactone has previously 
been demonstrated to improve cardiac hypertrophy and remodelling in hypertensive patients 
[51], although this was not shown in patients with T2DM [52].  In our population, there was 
some evidence that spironolactone decreased RWT and LVMI, suggesting a direct action of 
spironolactone on cardiac remodelling (that was independent of BP). If confirmed, this 
finding would be relevant because cardiac remodelling is a prognostic factor for CV events - 
even in the absence of LVH [53].  
Our results also suggest important differential actions of the two drugs on cardiac 
performance (S’ and E/A).  S’ is considered a sensitive TDI index of systolic function [54] 
which was increased by spironolactone compared with doxazosin. 
Spironolactone has previously been found to have beneficial effects on diastolic function [55, 
56]. In subclinical diabetic cardiomyopathy, spironolactone decreased conventional Doppler 
parameters (E/A), without affecting E/E’ [51], despite evidence of elevated LV diastolic 
filling pressure (E/E’ 14.3±7). We also observed a reduction in E/A ratio with spironolactone, 
with no change in E/E’, which was within the normal range at baseline. Therefore, the 
reduction in E/A may reflect an improvement in diastolic function that is not limited to 
alterations in pre-load, since other parameters sensitive to pre-load, such as EDV, ESV and 
LAVI were not affected by spironolactone, Table 2, (and neither were blood pressure or heart 
rate).  However, diastolic function is a complex phenomenon and a “single parameter” 
approach does not provide a comprehensive overview [38].  
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Overall, these results indicate that dietary nitrate may have BP-independent beneficial actions 
on myocardial remodelling over and above established effects of spironolactone. This could 
be explained by different mechanisms of action – mainly cardiac pre-load for dietary nitrate 
versus a direct anti-remodelling effect for spironolactone; although a direct action of 
nitrate/nitrite on the myocardium cannot be excluded and should be further investigated.  
We acknowledge several limitations of our study: cardiac analysis was not the primary 
outcome of the Vasera trial and our analyses are therefore exploratory; the overall sample 
size was relatively small (87 patients with follow-up data); confidence intervals are therefore 
wide; follow up data was incomplete, and the mixed effects model may not adequately 
account for any bias this could have introduced. 
 
Conclusion 
Six months' dietary nitrate decreased LV volumes ~5%, representing sustained, BP-
independent effects on cardiac structure, suggesting a beneficial action on cardiac 
remodelling, with potential consequences on CV prevention/treatment. Spironolactone 
independently decreased LV wall thickness and modified parameters of systo-diastolic 
function. 
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Table 1: Baseline Clinical and Cardiac Parameters of the Study Population  
  Doxazosin Spironolactone 
Placebo Juice Active Juice Placebo Juice Active Juice 
Patients n 27 16 20 24 
Sex -female n (%) 6 (22) 5 (31) 8 (40) 8 (33) 
Diabetes -at risk n (%) 11 (41) 6 (38) 6 (30) 12 (50) 
Previous CV event n (%) 1 ( 3.7) 2 (12.5) 2 (10.0) 2 (8.3) 
Smoker n (%) 3 (12.0) 2 (15.4) 2 (13.3) 1 (5.6) 
Age (years) mean (SD) 54.9 (13.8) 58.4 (14.7) 58.2 (9.9) 57.1 (13.2) 
BMI- Kg/m
2
) Mean (SD) 30.2 (5.1) 32.7 (6.5) 33.0 (4.2) 33.7 (5.2) 
SBP (mmHg) Mean (SD) 135.1 (16.8) 134.3 (16.6) 139.2(17.6) 138.3 (21.6) 
DBP (mmHg)  Mean (SD) 79.4 (11.1) 80.7 (8.2) 79.8 (11.8) 83.1 (15.6) 
HR (beat/min) Mean (SD) 73.3 (14.4) 70.2 (11) 73 (13.1) 66.7 (10.4) 
LAVI (ml/m
2
) Mean(SD) 23.0 (8.4) 25.3 (8.6) 25.6 (9.8) 24.9 (6.9) 
LVMI (g/m
2.7
) Mean(SD) 52.7 (12.6) 50.9 (11.9) 54.1 (15.2) 51.8 (10.5) 
RWT Mean(SD) 0.401 (0.064) 0.389 (0.068) 0.403 (0.057) 0.373 (0.052) 
EDV (ml) Mean(SD) 127.4 (35.7) 138.4 (45.6) 127.6 (19.3) 134.7 (34.1) 
ESV (ml) Mean(SD) 53.6 (16.9) 63.9 (29.7) 55.3 (10.7) 57.5 (15.2) 
Mass/Volume (g/ml) Mean(SD) 0.96 (0.33) 0.81 (0.23) 0.88 (0.24) 0.81 (0.23) 
E/A Mean(SD) 1.00 (0.30) 0.98 (0.31) 1.09 (0.66) 0.94 (0.26) 
DT (msec) Mean(SD) 233.0 (51.6) 232.4 (59.9) 212.3 (59.0) 220.3(53.6) 
E/E’ Mean(SD) 7.55 (2.16) 8.38 (2.70) 7.63 (2.29) 7.50 (2.23) 
EF (%) Mean(SD) 58.20 (3.1) 54.90 (5.3) 56.80 (4.2) 57.4 (3.7) 
S’ (cm/s) Mean(SD) 9.0 (1.6) 9.0 (1.7) 8.8 (2.1) 8.8 (1.2) 
 
Table 1: Baseline clinical and cardiac parameters of the study population. Abbreviations: 
systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR), left atrium 
volume index to body surface area (LAVI), left ventricular mass index (LVMI), relative wall 
thickness (RWT), end-diastolic volume (EDV), end-systolic volume (ESV), ratio of 
transmitral Doppler peak early (E) to late (A) filling velocity (E/A), ratio of transmitral 
Doppler peak early filling velocity (E) to pulsed-wave tissue-Doppler imaging (TDI)-derived 
early mitral annular diastolic velocity (E′) – (E/E’), early transmitral deceleration time (DT), 
ejection fraction (EF), pulsed-wave TDI-derived mitral annular systolic velocity – a systolic 
function index (S'), global longitudinal strain (GLS). 
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Table 2: Haemodynamic and Echocardiographic Parameters 
 Active juice 
(n=40) 
Placebo juice 
(n=47) 
Active vs 
placebo juice 
Spironolactone 
(n=44) 
Doxazosin 
(n=43) 
Spironolactone vs 
Doxazosin 
Haemodynamic  parameters 
SBP (mmHg) -6.34 (-9.09,-3.59) -6.57 (-9.41,-3.73) 0.23 (-3.77, 4.22) -6.49 (-9.31,-3.67) -6.42 (-9.20,-3.64) -0.07 (-4.07, 3.93) 
DBP (mmHg) -5.06 (-6.80,-3.33) -4.96 (-6.76,-3.17) -0.10 (-2.63, 2.43) -5.19 (-6.96,-3.42) -4.84 (-6.59,-3.09) -0.35 (-2.86, 2.16) 
HR (bpm) 0.14 (-1.51, 1.79) -0.94 (-2.65, 0.76) 1.08 (-1.33, 3.49) -0.05 (-1.73, 1.63) -0.76 (-2.41, 0.89) 0.71 (-1.67, 3.09) 
Morphological parameters 
LAVI (ml/m
2
) -1.59 (-2.64, -0.54) -0.26 (-1.29, 0.78) -1.33 (-2.83, 0.17) -0.69 (-1.69, 0.32) -1.16 (-2.24, -0.07) 0.47 (-1.05, 1.99) 
LVMI (g/m
2.7
) -0.96 (-1.60, -0.32) -1.16 (-1.75, -0.57) 0.20 (-0.68, 1.09) -1.48 (-2.08, -0.88) -0.63 (-1.28, 0.01) -0.85 (-1.76, 0.05) 
RWT -0.00 (-0.01, 0.00) -0.00 (-0.01, 0.00) -0.00 (-0.01, 0.01) -0.001 (-0.01, -0.00) 0.00 (-0.00, 0.001) -0.01 (-0.02, -0.00) 
EDV (ml) -4.77 (-8.10, -1.44) 1.56 (-1.67, 4.80) -6.33 (-11.1, -1.57) -2.36 (-5.52, 0.79) -0.85 (-4.26, 2.59) -1.51 (-6.28, 3.25) 
ESV (ml) -2.77 (-4.66, -0.89) 0.40 (-1.43, 2.22) -3.17 (-5.86, -0.48) -1.52 (-3.31, 0.27) -0.86 (-2.78, 1.07) -0.67 (-3.37, 2.03) 
Mass/Volume (g/ml) 0.01 (-0.01, 0.03) -0.03 (-0.05, -0.00) 0.04 (0.00, 0.07) -0.01 (-0.03, 0.02) -0.01 (-0.03, 0.02) 0.00 (-0.03, 0.04) 
Systo-diastolic function  parameters 
E/A -0.00 (-0.05, 0.10) -0.03 (-0.07, 0.02) 0.02 (-0.05, 0.10) -0.07(-0. 12, -0.02) 0.05 (-0.01, 0.10) -0.12 (-0.19, -0.04) 
DT (ms) 19.50 (8.40, 30.60) -0.24 (-10.6, 10.08) 19.74 (4.47, 36.01) 11.32 (0.82, 21.82) 7.93 (-3.42, 19.26) 3.39 (-12.5, 19.25) 
E/E’ 0.26 (-0.15, 0.68) -0.19 (-0.57, 0.19) 0.45 (-0.12, 1.02) -0.13 (-0.53, 0.26) 0.21 (-0.21, 0.62) -0.34 (-0.93, 0.24) 
EF (%) 0.46 (-0.29, 1.21) 0.09 (-0.64, 0.81) 0.38 (-0.69, 1.45) 0.38 (-0.34, 1.10) 0.17 (-0.60, 0.94) 0.21 (-0.88, 1.29) 
S’ (cm/s) -0.19 (-0.53, 0.15) 0.02 (-0.29, 0.34) -0.21 (-0.68, 0.26) 0.18 (-0.14, 0.50) -0.35 (-0.68, -0.01) 0.52 (0.05, 1.00) 
GLS (%) 0.72 (-0.43, 1.87) -0.58 (-1.88, 0.72) 1.30 (-0.48, 3.08) -0.44 (-1.68, 0.80) 0.58 (-0.61, 1.78) -1.02 (-2.77, 0.73) 
Table 2: Change from baseline, active nitrate-containing beetroot juice versus the placebo nitrate-depleted juice, and spironolactone versus 
doxazosin. Least square means (LSM) estimated from a model using data from all follow up visits, adjusted for baseline value, gender age, 
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ethnicity and diagnosis of diabetes. Data shown as LSM and 95% confidence intervals (CIs). Sets of data where the 95% CIs do not cross zero 
are highlighted in bold. Abbreviations: systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR), left atrium volume index 
to body surface area (LAVI), left ventricular mass index (LVMI), relative wall thickness (RWT), end-diastolic volume (EDV), end-systolic 
volume (ESV), ratio of transmitral Doppler peak early (E) to late (A) filling velocity (E/A), ratio of transmitral Doppler peak early filling 
velocity (E) to pulsed-wave tissue-Doppler imaging (TDI)-derived early mitral annular diastolic velocity (E′) – (E/E’), early transmitral 
deceleration time (DT), ejection fraction (EF), pulsed-wave TDI-derived mitral annular systolic velocity – a systolic function index (S'), global 
longitudinal strain (GLS). 
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Figure 1. Study Flow Diagram. At Visit 2, spironolactone dosage regimen was 12.5mg once 
daily for one week titrated to twice daily (indicated in the Diagram as (1-2x/d)); doxazosin 
was 2mg once daily for one week titrated to twice daily (indicated in the Diagram as (1-
2x/d)). At Visit 5 the doses of each were doubled, but frequencies maintained at twice daily 
(2x/d). 
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Figure 2. CONSORT flow diagram for VaSera trial and subsample of participants who had 
an echo at baseline and follow up visits. 
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Figure 3. Blood pressure (BP) responses to spironolactone and doxazosin: (A) change from 
baseline in systolic BP (SBP) for spironolactone and doxazosin; (B) overall effect of 
spironolactone versus doxazosin on SBP; (C) change from baseline in diastolic BP (DBP) for 
spironolactone and doxazosin; (B) overall effect of spironolactone versus doxazosin on DBP. 
Data shown as least square means (LSM) with 95% Confidence Intervals. 
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Figure 4. Blood pressure (BP) responses to dietary nitrate (beetroot juice): (A) change from 
baseline in systolic BP (SBP) for active nitrate-containing beetroot juice and placebo nitrate-
depleted juice; (B) overall effect of active nitrate-containing beetroot juice versus placebo 
nitrate-depleted juice on SBP; (C) change from baseline in diastolic BP (DBP) for active 
nitrate-containing beetroot juice and placebo nitrate-depleted juice; (B) overall effect of 
active nitrate-containing beetroot juice versus placebo nitrate-depleted juice on DBP. Data 
shown as least square means (LSM) with 95% Confidence Intervals. 
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Figure 5. Left ventricular (LV) volume responses, measured by echocardiography, to dietary 
nitrate (beetroot juice): (A) change from baseline in LV end-diastolic volume (LVEDV) for 
active nitrate-containing beetroot juice and placebo nitrate-depleted juice; (B) overall effect 
of active nitrate-containing beetroot juice versus placebo nitrate-depleted juice on LVEDV; 
(C) change from baseline in LV end-systolic volume (LVESV) for active nitrate-containing 
beetroot juice and placebo nitrate-depleted juice; (B) overall effect of active nitrate-
containing beetroot juice versus placebo nitrate-depleted juice on LVESV. Data shown as 
least square means (LSM) with 95% Confidence Intervals. 
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Figure 6. Echocardiographic systo-diastolic responses to spironolactone and doxazosin: (A) 
change from baseline in E/A ratio for spironolactone and doxazosin; (B) overall effect of 
spironolactone versus doxazosin on E/A ratio; (C) change from baseline in tissue Doppler 
systolic function index (S’) for spironolactone and doxazosin; (B) overall effect of 
spironolactone versus doxazosin on S’. Data shown as least square means (LSM) with 95% 
Confidence Intervals. 
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